



C4 Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2025 12:00 PM EST

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.

- **TD Cowen 45th Annual Healthcare Conference:**
 - Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the [Events & Presentations page](#) of the company's website. The archived replay of the webcast will be available for approximately 30 days following the live event.
- **Leerink Partners Global Healthcare Conference:**
 - Management will participate in the conference on March 9th in Miami, FL.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO[®] platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:

Investors:

Courtney Solberg

Senior Manager, Investor Relations

CSolberg@c4therapeutics.com

Media:

Loraine Spreen

Senior Director, Corporate Communications & Patient Advocacy

LSpreen@c4therapeutics.com